Valproic acid inhibits the protective effects of stromal cells against chemotherapy in breast cancer: Insights from proteomics and systems biology
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Interaction between tumor and stromal cells is beginning to be decoded as a contributor to chemotherapy resistance. Here, we aim to take a system‐level approach to explore a mechanism by which stromal cells induce chemoresistance in cancer cells and subsequently identify a drug that can inhibit such interaction. Using a proteomic dataset containing quantitative data on secretome of stromal cells, we performed multivariate analyses and found that bone‐marrow mesenchymal stem cells (BM‐MSCs) play the most protective role against chemotherapeutics. Pathway enrichment tests showed that secreted cytokines from BM‐MSCs activated 4 signaling pathways including Janus kinase‐signal transducer and activator of transcription, phosphatidylinositol 3‐kinase‐protein kinase B, and mitogen‐activated protein kinase, transforming growth factor‐β in cancer cells collectively leading to nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐kB) transcription factor activation. Based on the data from integrated Library of Integrated Network‐Based Cellular Signatures (iLINCs) program, we found that among different drugs, valproic acid (VA) affected the expression of 34 genes within the identified pathways that are activated by stromal cells. Our in vitro experiments confirmed that VA inhibits NF‐kB activation in cancer cells. In addition, analyzing gene expression data in patients taking oral VA showed that this drug decreased expression of antioxidant enzymes culminating in increased oxidative stress in tumor cells. These results suggest that VA confines the protective role of stromal cells by inhibiting the adaptation mechanisms toward oxidative stress which is potentiated by stromal cells. Since VA is an already prescribed drug manifesting anticancer effects, this study provides a mechanistic insight for combination of VA with chemotherapy in the clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, CoPISA models evidence from drug combinations in a way that supports more rational selection of drug pairs (3, 19) beyond traditional synergy scores.”
From DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay (2026) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Stromal cells in tumor microenvironment and breast cancer
Mao, Y., Keller, E. T., Garfield, D. H., Shen, K., & Wang, J. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9415-3 · Cited by 671 · cited 1×
“Aggressive tumors progressively educate their surrounding ecosystem to build a microenvironment composed of various stromal cell types including fibroblasts, endothelial cells, macrophages, and other immune cells (Figure 1), which offer survival benefits either by paracrine signaling or by direct contact.(4,5) Taking…”
Background
Research works printed but not linked: 64
- Wang S, 2009, Response to neoadjuvant therapy and disease free survival in patients with triple‐negative breast cancer, Gan to Kagaku Ryoho. Cancer Chemother, 36, 255
- 10.1016/j.bbacli.2015.03.003 · DOI · Paper page
- 10.1186/bcr3658 · DOI · Paper page
- 10.1016/j.bbalip.2015.07.005 · DOI
- 10.1016/j.ccr.2005.05.024 · DOI · Paper page
- 10.1021/pr700745n · DOI
- 10.1038/nm.1908 · DOI · Paper page
- 10.1038/nature12626 · DOI · Paper page
- 10.1007/s10549-012-2196-0 · DOI
- 10.18632/oncotarget.3099 · DOI · Paper page
- 10.1159/000366118 · DOI
- 10.1038/srep30133 · doi:10.1038/srep30133
- 10.1002/jcb.26183 · DOI
- 10.1038/nature11183 · DOI · Paper page
- Brock G, 2011, clValid, an R package for cluster validation, Journal of Statistical Software
- 10.1016/j.bbapap.2013.02.003 · doi:10.1016/j.bbapap.2013.02.003
- 10.1093/nar/gkw377 · DOI · Paper page
- Barneh F, 2015, Updates on drug‐target network; facilitating polypharmacology and data integration by growth of DrugBank database, Brief Bioinform, 17, 1070
- 10.1093/nar/gkx1037 · DOI · Paper page
- 10.4103/2277-9175.148291 · DOI
- 10.1081/CLT-120014645 · DOI · Paper page
- 10.4103/0973-1482.147254 · doi:10.4103/0973-1482.147254
- 10.1200/PO.16.00011 · DOI
- 10.1093/bioinformatics/btg405 · DOI · Paper page
- 10.1007/0-387-29362-0_23 · DOI · Paper page
- Wickham H, 2010, ggplot2: elegant graphics for data analysis, J Stat Softw, 35, 65
- 10.1155/2013/857895 · doi:10.1155/2013/857895
- 10.1016/j.celrep.2017.02.006 · DOI · Paper page
- 10.1093/jnci/djm135 · DOI · Paper page
- 10.3390/ijms13089545 · DOI · Paper page
- 10.1016/j.tcb.2014.11.006 · DOI · Paper page
- 10.1016/j.canlet.2015.07.044 · DOI · Paper page
- 10.3892/or.2015.4047 · DOI
- 10.1038/cr.2010.178 · DOI · Paper page
- 10.1021/acs.jmedchem.6b01243 · DOI · Paper page
- 10.18632/oncotarget.1658 · DOI
- 10.1038/s41467-017-02746-z · DOI · Paper page
- 10.1038/nrc3599 · DOI · Paper page
- 10.1038/bjc.2012.201 · DOI · Paper page
- 10.1016/j.canlet.2007.10.006 · DOI
- 10.3325/cmj.2017.58.349 · DOI
- 10.1080/15548627.2015.1082024 · DOI · Paper page
- 10.3892/ol.2016.4880 · DOI
- 10.1155/2010/479364 · DOI · Paper page
- Kostrouchová M, 2007, Valproic acid, a molecular lead to multiple regulatory pathways, Folia Biol, 53, 37, 10.14712/fb2007053020037 · DOI
- 10.1039/C5TX00476D · DOI
- 10.1002/pros.20587 · DOI
- 10.1016/j.biocel.2008.08.019 · DOI
- 10.1016/j.mce.2009.09.011 · DOI
- 10.3892/ijo.2015.3213 · DOI
- 10.1517/13543784.2013.853037 · DOI
- 10.1186/1756-8722-3-5 · DOI · Paper page
- 10.1586/14737140.2014.940329 · DOI
- 10.1158/1055-9965.EPI-08-0646 · DOI
- 10.1677/joe.1.06970 · DOI · Paper page
- 10.1158/0008-5472.CAN-13-1117 · DOI
- 10.3390/antiox7010016 · DOI
- 10.1155/2012/762825 · DOI · Paper page
- 10.4236/mc.2012.11001 · doi:10.4236/mc.2012.11001
- 10.1155/2016/4502846 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-0814 · DOI
- 10.1124/mol.111.072314 · DOI · Paper page
- 10.1093/neuonc/nop005 · DOI · Paper page
- Barneh F, 2017, A rational drug combination design to inhibit epithelial‐mesenchymal transition in a three‐dimensional microenvironment, bioRxiv, 148767
Cited by
DORSSAA: Drug-Target interactOmics Resource Based on Stability/Solubility Alteration Assay
Zangene, E., Gholizadeh, E., Schwämmle, V., Saei, A. A., Wilhelm, M., Käll, L., & Jafari, M. (2026) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2026.101603 · Cited by 3
Self-citation
Metadata
- Authors
- Barneh, F., Salimi, M., Goshadrou, F., Ashtiani, M., Mirzaie, M., Zali, H., & Jafari, M.
- Affiliations
- Department of Basic Sciences Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences Tehran Iran
- Physiology and Pharmacology Department Pasteur Institute of Iran Tehran Iran
- Drug Design and Bioinformatics Unit, Medical Biotechnology Department Biotechnology Research Center, Pasteur Institute of Iran Tehran Iran
- Department of Applied Mathematics Faculty of Mathematical Sciences, Tarbiat Modares University Tehran Iran
- School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical sciences Tehran Iran
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2018-06-28
- Volume
- 119
- Issue
- 11
- Pages
- 9270-9283
- ISSN
- 0730-2312
- 1097-4644
- Cited by
- 14
- References
- 2
- Language
- en
- Funders
- Cancer Research Network of Iran
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.